Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Marseille

2 abstracts

Abstract
ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2- metastatic breast cancer: A phase 3 trial.
Org: Institut Curie, Saint Cloud, France, Paris and Saint Cloud, France, Centre Oscar Lambret, Lille University Hospital,
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.
Org: Institut de Cancerologie de l'Ouest, ICO Institut de Cancerologie de l'Ouest, Institut de Cancérologie de l'Ouest, Centre Antoine Lacassagne, Centre Georges Francois Leclerc,